Medically reviewed by Dr. Rajeev Agarwal, MBBS, Medical Director: Infertility Specialist, IVF Expert and Gynaecologist at Renew Healthcare, Kolkata
Last updated: July 2026
In brief: A low AMH tells you how many eggs are likely to respond to stimulation. It does not tell you the quality of those eggs, it does not mean you cannot conceive, and it is not a countdown to early menopause. The strategies that genuinely help are about accumulating embryos over time rather than forcing one cycle to produce more eggs than the ovaries can give.
What a low AMH actually means, and what it does not
Anti-Müllerian hormone is produced by small developing follicles in the ovary. Measuring it gives a reasonable estimate of the size of the remaining follicle pool.
That is genuinely useful information. It helps predict how your ovaries will respond to stimulation drugs, which in turn shapes protocol choice, drug dosing and expectations. It is one of the two best tests we have, alongside the antral follicle count on ultrasound.
But the way low AMH is communicated causes an enormous amount of unnecessary fear, so let us be precise about the limits of the test.
AMH measures quantity, not quality. It says something about how many eggs may respond. It says nothing about whether those eggs are chromosomally normal. Age remains the best available indicator of egg quality, which is why a 32-year-old with low AMH and a 42-year-old with the same AMH are in genuinely different situations, even though the number on the report is identical.
A low AMH is not a diagnosis of infertility. Women with low AMH conceive naturally. The test was developed to predict ovarian response to stimulation, and that is what it does best.
AMH is not a menopause prediction test. Low AMH is associated with an earlier menopause at a population level, but it cannot tell an individual woman when hers will occur, and it certainly does not mean it is imminent.
Numbers vary between laboratories. Different assays and different units, ng/mL versus pmol/L, produce different figures for the same woman. A value from one lab is not directly comparable to a value from another. If you are tracking your AMH, use the same laboratory.
The single most damaging sentence in fertility medicine is "your AMH is low, you have the ovaries of a much older woman." It is scientifically sloppy and it frightens people into decisions they would not otherwise make. AMH is a stimulation-response predictor, nothing more.
How poor ovarian reserve is properly assessed
A single AMH value is not enough to make a plan. A proper assessment includes:
| Assessment | What it adds |
|---|---|
| AMH | Estimate of the remaining follicle pool; predicts response |
| Antral follicle count (AFC) on transvaginal ultrasound | Direct visual count; complements AMH and catches assay errors |
| Age | The strongest predictor of egg quality |
| Day 2 to 3 FSH and oestradiol | Older test; still useful, particularly when markedly raised |
| Previous response to stimulation | If you have had a cycle, this is the most informative data of all |
| History | Previous ovarian surgery, endometriosis, chemotherapy, family history of early menopause, autoimmune conditions |
If you have already had one stimulated cycle, how your ovaries actually behaved outranks every predictive test. Real response beats predicted response.
Why this is classified, and why it matters to your plan
Reproductive medicine now groups women with reduced ovarian response rather than lumping them together. The widely used POSEIDON framework separates patients by two things: age (under or over 35) and whether poor response has already been demonstrated in a previous cycle.
The reason this matters to you is practical. It changes:
- Whether the goal is a better protocol or more cycles
- Whether adjuvants are worth trying
- How soon donor eggs should be discussed
- What "success" should be defined as for a single cycle
A 33-year-old with low AMH who has never been stimulated needs a different conversation from a 40-year-old who has already had two cycles yielding two eggs each. Both may be told "poor ovarian reserve." Their plans should not look the same.
The strategies that genuinely help
1. Change the goal: accumulate embryos, don't chase eggs
This is the most important shift in thinking, and it is what separates a good plan from a frustrating one.
If your ovaries can produce three eggs, no protocol will make them produce fifteen. Pushing the dose higher past a certain point does not overcome a limited follicle pool, it mostly increases cost and side effects.
So the winning strategy is usually not to maximise one cycle. It is to run several manageable cycles and bank the embryos, then transfer when you have accumulated a reasonable number. Two or three eggs per cycle over three cycles is a very different proposition from two or three eggs once.
This reframing helps emotionally too. A cycle that produces two good embryos is a successful cycle for someone with low reserve. It is only a failure if it was measured against the wrong benchmark.
2. Get the protocol right rather than the dose high
Reasonable protocol strategies in poor responders include antagonist protocols, adjusted starting doses, and in selected patients approaches such as dual stimulation within a single menstrual cycle (DuoStim), collecting from both the follicular and luteal phases to gather more eggs in less calendar time. That last approach is particularly relevant when age means time is the scarce resource.
There is no single best protocol for poor responders. Anyone who tells you otherwise is overselling. What matters is that the plan is individualised and revised based on how you actually responded.
3. Do not lose time
For women with low ovarian reserve, delay is the most expensive variable. Reserve declines, and egg quality declines with age. A six-month wait for a "better protocol" or a course of supplements usually costs more than it gains.
If low AMH has been found and you want a child, the honest advice is to start the conversation about treatment now, and do the optimising in parallel.
4. Consider freezing embryos rather than eggs, where appropriate
Where there is a partner or donor sperm and no reason to defer, embryos generally give more reliable information than frozen eggs, you know fertilisation occurred and you know how the embryo developed. This is a discussion to have specifically, not a rule.
Adjuvants and supplements: graded honestly
This is where a great deal of money is spent on the basis of very thin evidence. Here is a fair reading.
| Adjuvant | Honest status |
|---|---|
| DHEA | Widely used in poor responders; evidence remains inconsistent and of limited quality. Some centres use it, many do not. Not a proven intervention. |
| CoQ10 | Biologically plausible mechanism, popular, but robust live-birth evidence is lacking. |
| Growth hormone | Studied as an adjuvant in poor responders with mixed results; expensive; not established as standard care. |
| Testosterone or androgen priming | Investigated, inconsistent results, not established. |
| Melatonin, myo-inositol, vitamin D | Some rationale; evidence weak for improving live birth in poor responders specifically. |
| "Ovarian rejuvenation" procedures (PRP, stem-cell injection) | Experimental. Should be regarded as research, not treatment, and should not be sold as an established option. |
None of these will raise your AMH in any way that changes the number of eggs your ovaries can produce. Some may be reasonable to trial, at modest cost, alongside treatment. None justifies delaying treatment, and none justifies significant expense.
If a clinic's plan for low AMH is primarily a package of supplements and a "rejuvenation" procedure, get a second opinion.
When donor eggs enter the conversation
This conversation should be raised honestly, early, and without pressure.
It becomes relevant when repeated well-run cycles yield no viable embryos, when age has substantially reduced egg quality, or when the couple decides that the emotional and financial cost of continuing has reached its limit.
Two things are worth saying clearly.
First, discussing donor eggs is not the same as recommending them. A good specialist raises it so that you know the option exists and can weigh it, not to push you towards it.
Second, it is genuinely a difficult decision with emotional, family and sometimes cultural dimensions, and it deserves proper time and counselling rather than a two-minute mention at the end of a consultation.
In India, donor gamete use is regulated under the ART (Regulation) Act, 2021, and any clinic offering it should be able to explain the current legal requirements to you clearly.
What to ask at your next appointment
- What is my AMH and my antral follicle count, and do they agree with each other?
- Given my age, is the main concern quantity, quality, or both?
- What number of eggs is realistic for me in one cycle?
- Is the plan to maximise one cycle or to bank embryos over several?
- What would you change if this cycle responds poorly?
- At what point would you advise me to consider donor eggs?
- What is the total realistic cost of a three-cycle banking plan, including medication and freezing?
Frequently asked questions
Can I increase my AMH?
No treatment reliably and durably raises AMH in a way that increases the number of eggs available. Values do fluctuate somewhat between tests and are affected by hormonal contraception. Focus on treatment strategy rather than on moving the number.
Does low AMH mean I will have early menopause?
Not necessarily. Low AMH is associated with earlier menopause across populations but cannot predict it for an individual. Many women with low AMH have menstrual cycles for years afterwards.
Can I conceive naturally with low AMH?
Yes. AMH predicts response to stimulation far better than it predicts natural conception, particularly in younger women. Low AMH reduces the number of eggs available; it does not switch off ovulation.
Is IVF worth doing with low AMH?
Often yes, but the goal should be defined realistically: accumulating embryos across cycles rather than one large harvest. Your age and any previous response are the key factors in that decision.
Should I do IVF or keep trying naturally?
This depends on age, how long you have been trying, whether there are other factors such as tubal or male factor, and your own tolerance for waiting. Low AMH alone in a young woman with no other issues is not automatically an indication for immediate IVF.
Does a low AMH mean my eggs are poor quality?
No. AMH is a quantity marker. Egg quality tracks with age far more than with AMH.
My AMH differs between two labs. Which is right?
Both may be technically correct, different assays and units give different values. Use one laboratory consistently and interpret alongside your antral follicle count.
The bottom line
Low AMH is a planning problem, not a closed door.
It tells your doctor how many eggs to expect per cycle, which should change the strategy, bank embryos across several manageable cycles rather than trying to force one big one, and it should change the timeline, because delay costs more here than anywhere else in fertility medicine.
What it does not tell you is the quality of your eggs, whether you can conceive naturally, or when your menopause will be. Anyone using your AMH to answer those three questions is over-reading the test.
Get a realistic plan for your ovarian reserve
Dr. Rajeev Agarwal assesses ovarian reserve and designs individualised low-response protocols at Renew Healthcare, Kolkata, with honest expectations about egg numbers, cycle strategy and cost before you begin.
Book a consultation: 062922 69060 | renewhealthcare.in | Ground Floor, 18 C, Mandeville Gardens, Ekdalia, Ballygunge, Kolkata, West Bengal 700019
This article is for general education and does not replace individual medical advice. Please consult a qualified specialist about your own situation.